Next-Gen Oral Obesity Drugs
Novo Nordisk has partnered with U.S.-based Septerna in a deal worth up to $2.2 billion to co-develop oral small molecule therapies targeting obesity and related cardiometabolic diseases. This includes $200M upfront & near-term payments, with the rest tied to milestones.
💊 Why it matters:
The goal is to create oral alternatives to blockbuster injectable GLP-1 drugs like Wegovy and Ozempic—easier to store, ship, and take.
🧪 Septerna’s platform targets multiple incretin receptors (GLP-1, GIP, and glucagon) via a single molecule. Early preclinical data shows:
Oral GIP agonist + semaglutide → 33% weight loss in mice, rivaling Lilly’s tirzepatide.
⚙️ Deal highlights:
- Joint discovery & development until IND stage
- Novo takes over full R&D from there
- Septerna may opt for profit-sharing on one program
This deal fortifies Novo’s pipeline as it races against Eli Lilly in the oral obesity drug arms race.
🧬 The next phase of weight-loss innovation may just come in pill form.
About SciFocus News
SciFocus News is a dedicated science communication platform that brings the latest research breakthroughs, innovations, and scientific stories to a broader audience. With a mission to make complex science accessible and engaging, SciFocus highlights cutting-edge discoveries, researcher spotlights, biotech updates, and real-world applications of science from academia, startups, and industry.
Follow SciFocus Newsletter to stay inspired, informed, and connected to the science that matters.
https://www.linkedin.com/newsletters/biopatrika-6915078341121191936/
